# Semax

**Category:** peptide
**Evidence Grade:** C
**Risk Profile:** low

## Description
A synthetic analogue of ACTH(4-7) developed in Russia, approved for cognitive enhancement and neuroprotection. Enhances BDNF, NGF, and has robust nootropic effects. Extensively studied in Russian clinical settings for stroke recovery and cognitive decline.

## Mechanisms of Action
- BDNF and NGF upregulation
- Dopamine and serotonin modulation
- Neuroprotection via anti-inflammatory pathways
- Improved cerebral blood flow

## Dosage
- **Standard:** 200-600mcg intranasal, 2-3x/day
- **Range:** 100-900mcg/day
- **Notes:** Intranasal drops or spray. Approved in Russia and Ukraine. 10-14 day courses typical.

## Key Findings
- Improved cognitive performance and memory in clinical trials
- Accelerated recovery from ischemic stroke in Russian clinical data
- Upregulated BDNF expression by 4-8x in animal hippocampus

## Interactions
- May interact with stimulants or ADHD medications

## Side Effects
- Nasal irritation
- Mild headache
- Irritability at high doses

## Contraindications
- Acute psychosis
- Seizure disorders
- Pregnancy

## Sources


## Suppliers


---
*Last updated: 2026-02-04T14:50:14.777Z*
